S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Microbot Medical Inc. (NASDAQ:MBOT), a medical device company with a market capitalization of $190 million, reported Monday it issued a total of 2,967,953 shares of its common stock from August 11 through Monday upon the exercise of various series of preferred investment options. The company, whose stock has surged over 240% year-to-date according to InvestingPro data, also issued 47,218 shares to a former director upon the exercise of incentive options, according to a statement based on a recent SEC filing.
The newly issued shares resulted from the exercise of 104,103 Series E preferred investment options at $1.50 per share, 467,144 Series G options at $1.75 per share, and 2,349,488 Series H options at $2.10 per share. The aggregate gross proceeds from these transactions amounted to approximately $5.9 million before placement agent fees and expenses. The company maintains strong financial health with a current ratio of 12.06, indicating robust liquidity and minimal debt on its balance sheet.
The shares underlying the Series E options were registered for resale on Registration Statement Form S-3 (Registration No. 333-276487), while the shares from Series G and Series H options were registered on Form S-3 (Registration No. 333-284688).
All shares were issued under an exemption provided by Section 4(a)(2) of the Securities Act of 1933, as transactions not involving a public offering.
Following these issuances, Microbot Medical reported approximately 48,513,892 shares of common stock outstanding as of Monday. The company’s common stock is listed on the NASDAQ Capital Market under the ticker MBOT.
In other recent news, Microbot Medical Inc. has reported several noteworthy developments. The company successfully raised $3 million through the exercise of Series F and Series G preferred investment options, as disclosed in a recent SEC filing. This capital was generated by issuing 1,808,336 shares of common stock, with Series G options exercised at $1.75 per share and Series F options at $1.50 per share. Additionally, Microbot Medical received a new patent in China for its surgical robotics technology, enhancing its intellectual property portfolio, which now includes nine granted patents globally. H.C. Wainwright maintained its Buy rating for Microbot Medical, following the grant of a U.S. patent for its LIBERTY endovascular robotic system. The firm set a price target of $9.00 for the company. In leadership news, Microbot Medical appointed Christina Bailey as Vice President of Sales, bringing her 20 years of experience in medical device sales. Brenmiller Energy Ltd. appointed Harel Gadot, Microbot Medical’s CEO, as an independent director to its board, effective immediately.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.